Hyderabad, India-based Aurobindo Pharma’s U.S. subsidiary Aurobindo Pharma USA Inc signed a pact to acquire an under-development product and certain related assets from Australia’s Advent Pharmaceuticals Pty Ltd., for $12.5 million. The time period for completion of the deal is January 2019.
Advent is a specialty pharmaceutical R&D company based in Melbourne, Australia, that develops generic inhaled products for global markets. This acquisition provides an opportunity to acquire assets for specialty generics business, Aurobindo Pharma said.
